Table 3

Therapeutic anticoagulation therapy (OAC)

IndicationTherapyDuration of therapyGuideline
Non-valvular atrial fibrillation or atrial flutter with CHA2DS2-VASc ≥2DOAC or VKALifelong2016 ESC Guidelines for the management of atrial fibrillation.14
Atrial fibrillation >48 hours existing for which cardioversion is indicated and CHA2DS2-VASc <2DOAC or VKAAt least 3 weeks prior to cardioversion until 4 week after cardioversion2016 ESC Guidelines for the management of atrial fibrillation.14
Venous thromboembolismDOAC or VKA3 months to lifelong2016 FMS Antithrombotisch beleid
(Antithrombotic policy)15
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European
Respiratory Society.16
Mechanical valveVKALifelong2017 ESC Guidelines for the management of valvular heart disease.12
Biological mitral of tricuspidal valve <3 months (implantation or reconstruction)VKA3 months, followed by lifelong SAPT2017 ESC/EACTS Guidelines for the management of valvular heart disease.10
  • EACTS, European Society of Cardio-Thoracic Surgery; ESC, European Society of Cardiology; FMS, Federatie Medisch Specialisten; VKA, vitamin K antagonists.